Also known as Glucophage, Glucophage XR, Fortamet, Riomet, and Glumetza.
PIONEER TEENS phase 3a: first oral GLP‑1 RA trial in 10–17‑year-olds with type 2 diabetes (n=132). 52‑week, placebo‑controlled; safety matched adult trials; regulatory filings planned H2.
Triple-agonist UBT251 (GLP-1/GIP/glucagon) induced up to 9.8% weight loss, improved BP and lipids vs placebo/semaglutide. Safety consistent with triple-G class; global phase-2 and China phase-3 planned
Orforglipron 36 mg reduced A1C by 2.2% and weight by 9.2%, surpassing semaglutide in a 52-week trial with 1,698 participants. Results published in The Lancet.
CagriSema showed superior HbA1c reduction and weight loss over semaglutide in a 68-week trial with type 2 diabetes patients inadequately controlled with metformin.
Amycretin shows significant HbA1c reduction and weight loss in type 2 diabetes patients, with a safe profile. Phase 3 trials planned for 2026.
